NCT03414502
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
Recruiting · Phase 3 · University of Nebraska · registry updated 2026-06-17
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure. Current treatment goals are to minimize pain, limit joint damage, and prevent loss of function. Drugs used to treat RA include non-steroidal anti-inflammatory drugs (NSAIDS), glucocorticoids, and disease-modifying anti-rheumatic drugs (DMARDs), including biologics. Methotrexate (MTX) is the DMARD of choice in the treatment of RA, because it has been shown to be both well-tolerated and effective in achieving clinical response and slowing radiographic progression of disease. However, this drug alone results in remissions in only a small subset of patients and reliable predictors of DMARD response have yet to be identified. This study is open-label of 16-weeks duration to identify factors that help predict clinical responses to disease-modifying antirheumatic drugs (DMARD) therapies for rheumatoid arthritis (RA) participants. All participants will receive a starting dose of DMARD medication(s) which may be adjusted by the investigator as needed....
Inclusion
- Diagnosed rheumatoid arthritis (RA) with 4 of 7 American College of Rheumatology criteria
- Morning stiffness for at least 1 hour for at least 6 weeks
- Swelling of 3 or more joints for at least 6 weeks
- Swelling of wrist, metacarpophalangeal (MCP), or proximal interphalangeal joints for 6 or more weeks
- Symmetric joint swelling
- Hand x-rays with erosions or bony decalcifications
Exclusion
- Pregnant or breastfeeding women
- Men and women of child bearing potential unwilling to practice effective method of contraception